Mode and site of action of therapies targeting CGRP signaling

Table 3 Anti-CGRP monoclonal antibodies

Monoclonal antibodies	Erenumab	Galcanezumab	Fremanezumab	Eptinezumab
Target	CGRP receptor	CGRP ligand	CGRP ligand	CGRP ligand
IgG type	IgG2, human	IgG4, humanized	IgG2a, humanized	IgG1, humanized
Administration	Monthly SC	Monthly SC	Monthly or quarterly SC	Quarterly IV
Doses approved for migraine prevention (EM, CM)	70 mg or 140 mg	120 mg (240 mg loading dose)	225 mg monthly or 675 mg quarterly	100 mg or 300 mg
Other headache disorders (approved or under investigation)	cCH, PTH	eCH (approved 300 mg monthly), cCH (no primary endpoint met)	eCH and cCH (primary endpoint unlikely to be met), PTH	eCH, cCH

Abbreviations: cCH Chronic cluster headache, eCH Episodic cluster headache, IV Intravenous, SC Subcutaneous injection, PTH Acute post-traumatic headache

ISSN: 1129-2377